Actavis PLC (ACT.N)

ACT.N on New York Stock Exchange

279.12USD
23 Jan 2015
Change (% chg)

$1.11 (+0.40%)
Prev Close
$278.01
Open
$277.65
Day's High
$280.24
Day's Low
$276.90
Volume
570,658
Avg. Vol
485,449
52-wk High
$280.24
52-wk Low
$175.00

ACT.N

Chart for ACT.N

About

Actavis PLC, is a global, integrated specialty pharmaceutical company. The Company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company produces and markets generic, branded generic, branded and over-the-counter (OTC) pharmaceutical products covering all therapeutic classes.... (more)

Overall

Beta: 0.28
Market Cap(Mil.): $73,983.86
Shares Outstanding(Mil.): 265.06
Dividend: --
Yield (%): --

Financials

  ACT.N Industry Sector
P/E (TTM): -- 40.21 40.82
EPS (TTM): -4.18 -- --
ROI: -3.50 19.07 18.35
ROE: -6.36 19.85 19.25
Search Stocks

Richter and Actavis say Cariprazine effective on schizophrenia relapse

BUDAPEST - Hungarian drug maker Richter and its partner Actavis on Tuesday said a Phase III trial had positive results in anti-psychotic drug Cariprazine's effects to prevent relapse for schizophrenia patients.

20 Jan 2015

Richter and Actavis say Cariprazine effective on schizophrenia relapse

BUDAPEST, Jan 20 - Hungarian drug maker Richter and its partner Actavis on Tuesday said a Phase III trial had positive results in anti-psychotic drug Cariprazine's effects to prevent relapse for schizophrenia patients.

20 Jan 2015

Actavis aims to add Allergan CEO to its board: sources

SAN FRANCISCO - Allergan Inc Chief Executive David Pyott is close to joining the board of directors of Actavis Plc , which reached a deal to buy the Botox-maker for $66 billion in November, three people familiar with the matter said on Thursday.

16 Jan 2015

FDA denies approval for Actavis hypertension treatment

- Generic drug maker Actavis Plc said the U.S. health regulator denied an approval for its hypertension treatment, a fixed-dose combination of nebivolol and valsartan.

25 Dec 2014

CORRECTED- FDA denies approval for Actavis hypertension treatment

Dec 24 - Generic drug maker Actavis Plc said the U.S. health regulator denied an approval for its hypertension treatment, a fixed-dose combination of nebivolol and valsartan.

25 Dec 2014

Actavis, Adamas win FDA approval for Alzheimer's drug

- The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc.

24 Dec 2014

Actavis, Adamas win FDA approval for Alzheimer's drug

Dec 24 - The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc.

24 Dec 2014

Exclusive: Express Scripts presses for expansion of drugs it won't cover

LOS ANGELES - Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year.

23 Dec 2014

Exclusive: Express Scripts presses for more drug savings with coverage list

LOS ANGELES - Express Scripts , the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year.

23 Dec 2014

Spain's Almirall gains on report of Actavis interest

Dec 19 - Shares in Spanish drugmaker Almirall jumped 9 percent on Friday after a Bloomberg report of potential takeover interest from Actavis.

19 Dec 2014

Earnings vs. Estimates

Search Stocks